Adeona Pharmaceuticals, Inc. (aen) - Financial And Strategic Analysis Review -- Aarkstore Enterprise

Adeona Pharmaceuticals, Inc

Adeona Pharmaceuticals, Inc. (AEN) - Financial and Strategic Analysis Review

Adeona Pharmaceuticals, Inc. (Adeona), public shareholding company is a development-stage specialty pharmaceutical company. It principally focuses on the treatment of ophthalmic, neurologic and autoimmune diseases. The company's key products in various clinical development stages include TRIMESTA (Phase IIb clinical trial), an oral immunomodulatory and anti-inflammatory bio-identical estrogenic agent to treat post-menopausal hot flashes; Oral dnaJP1 for the induction of immune tolerance in rheumatoid arthritis; and Oral Flupirtine, a non-opiate non-addictive oral therapy for fibromyalgia and other ophthalmic indications. Adeona is headquartered at Ann Arbor in Michigan, the US

Adeona Pharmaceuticals, Inc. Key Recent Developments

May 17, 2010: Adeona Pharmaceuticals Reports Net Loss Of $1 Million For Q1 2010

Mar 16, 2010: Adeona Names Jeff Riley As Board Director

Feb 09, 2010: Adeona Names James Kuo As Chairman, CEO And President

Jan 08, 2010: Adeona Wins Additional $860,000 Grant For Oral Estriol Multiple Sclerosis Clinical Trial

Jan 08, 2010: Adeona Receives Additional $860,000 Grant For Trimesta Clinical Trial

This comprehensive SWOT profile of Adeona Pharmaceuticals, Inc. provides you an in-depth strategic analysis of the companys businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of the Profile on Demand service, covering over 50,000 of the worlds leading companies. Once purchased, the highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Adeona Pharmaceuticals, Inc., including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days (excluding weekends).

The profile contains critical company information including*,

- Business description A detailed description of the companys operations and business divisions.

- Corporate strategy Analysts summarization of the companys business strategy.

- SWOT Analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.

- Company history Progression of key events associated with the company.

- Major products and services A list of major products, services and brands of the company.

- Key competitors A list of key competitors to the company.

- Key employees A list of the key executives of the company.

- Executive biographies A brief summary of the executives employment history.

- Key operational heads A list of personnel heading key departments/functions.

- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

For more information please visit :

http://www.aarkstore.com/reports/Adeona-Pharmaceuticals-Inc-AEN-Financial-and-Strategic-Analysis-Review-52040.html

by: Aarkstore Enterprise

Adeona Pharmaceuticals, Inc. (aen) - Financial And Strategic Analysis Review -- Aarkstore Enterprise

Adeona Pharmaceuticals, Inc

Contact

www.yloan.com

Products

Our Solutions

Press Room

Resources